Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883619 | 0.87 | AOC3 (0.35) | AOC3MAPTMAOBTP53SMN1; SMN2 | |
| SCHEMBL4888161 | 0.82 | RPS6KB2 (0.38) | MAPTGAASMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL4888480 | 0.81 | AOC3 (0.53) | AOC3MAOBSMN1; SMN2KMT2A | |
| SCHEMBL4882505 | 0.79 | ALDH1A1 (0.39) | AOC3MAPTMAOBMEN1ALDH1A1 | |
| SCHEMBL14281007 | 0.78 | KDM4E (0.40) | AOC3MAPTMAOBMEN1ALDH1A1 | |
| SCHEMBL17716402 | 0.66 | SCN9A (0.36) | AOC3MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL4889944 | 0.66 | AOC3 (0.48) | AOC3MAOBSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL4882620 | 0.65 | AOC3 (0.55) | AOC3MAOBSMN1; SMN2KMT2A | |
| SCHEMBL1443502 | 0.65 | AOC3 (0.67) | AOC3MAOB | |
| SCHEMBL4887034 | 0.65 | AOC3 (0.55) | AOC3MAOBSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1791835-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006028269-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 163/4885MAPT 1178/4885GAA 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.